Evidence map›Paper›PMID 41559473›Full record

ArticleEMBO reports2026

Hyperactivation of mTORC1 blocks stem cell fate transitions through TFE3-NuRD association.

Peizhi Li, Shuhui Xu, Xinyu Wu, Yin Gao, Tanveer Ahmed, Yinghua Huang, Dajiang Qin, Baoming Qin, Lulu Wang, Xueting Xu

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peizhi Li *Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0009-0009-4966-2754
Shuhui Xu *Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0009-0008-6946-1629
Xinyu WuGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0000-0002-5293-5479
Yin GaoGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0009-0004-4783-6187
Tanveer AhmedGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0000-0003-0519-2315
Yinghua HuangGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China.ORCID http://orcid.org/0000-0002-2028-8131
Dajiang QinKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510799, China.
Baoming QinGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China. qinbaoming@genomics.cn.
Lulu WangKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510799, China. wang_lulu@gzhmu.edu.cn.ORCID http://orcid.org/0009-0006-7438-5486
Xueting XuGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, 510530, China. xu_xueting@gibh.ac.cn.ORCID http://orcid.org/0000-0002-8011-7449

Funding

the China Postdoctoral Science Foundation 2024T170933the National Key Research and Development Program of China 2021YFA1100401the National Natural Science Foundation of China 32070861the National Natural Science Foundation of China 32300664the National Natural Science Foundation of China 32370849the Science and Technology Planning Project of Guangdong Province, China 2023B1212060050
6 · The paper itself

Abstract

Mechanistic target of rapamycin complex 1 (mTORC1) integrates signals from nutrients, growth factors, and cellular stress to regulate biosynthesis and maintain homeostasis. Dysregulated mTORC1 disrupts stem cell homeostasis and impairs cell fate transitions in vivo and in vitro. Previous studies have shown that mTORC1 hyperactivation promotes nuclear translocation of TFE3, blocking pluripotency exit in both mouse and human naïve embryonic stem cells. Similarly, our earlier work has demonstrated that sustained mTORC1 activation impedes somatic cell reprogramming via the transcriptional coactivator PGC1α. This raises the question of how mTORC1 coordinates gene transcription across distinct transitions in pluripotent cells. Here, we show that TFE3 mediates the transcriptional blockade induced by mTORC1 hyperactivation during reprogramming. Notably, during both pluripotency exit and reprogramming, TFE3 recruits the NuRD corepressor complex to repress genes essential for cell fate transitions. These findings uncover a shared mechanism by which mTORC1 and TFE3 regulate stem cell identity, highlighting the dual regulatory role of TFE3 and its potential implications in development, aging, and tumorigenesis.

Indexed as

mTORC1NuRD ComplexPluripotency ExitSomatic Cell ReprogrammingTFE3

Identifiers

PMID41559473
PMCPMC12936182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.